DiaMedica Therapeutics (DMAC) Notes Payables (2017)
DiaMedica Therapeutics' (DMAC) quarterly Notes Payables came in at $84000.0 in Q4 2017.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Notes Payables (2017) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Notes Payables for 1 consecutive years, with $84000.0 the latest figure, recorded in Q4 2017.
- For the quarter ending Q4 2017, Notes Payables changed N/A year-over-year to $84000.0; the trailing twelve-month figure through Dec 2017 stood at $84000.0 (changed N/A YoY), and the FY2017 full-year result was $84000.0, changed N/A from the prior year.
- Notes Payables held at $84000.0 in Q4 2017 per DMAC's latest filing.
- Across five years, Notes Payables topped out at $84000.0 in Q4 2017 and bottomed at $84000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | DiaMedica Therapeutics | 364.00 Mn | 364.00 Mn | - |